Skip to main content

Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial.

Author
Abstract
:

The AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity.

Year of Publication
:
2019
Journal
:
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
Volume
:
15
Issue
:
8
Number of Pages
:
1348-1354
ISSN Number
:
1550-7289
URL
:
https://linkinghub.elsevier.com/retrieve/pii/S1550-7289(18)31266-8
DOI
:
10.1016/j.soard.2019.04.026
Short Title
:
Surg Obes Relat Dis
Download citation